Norfloxacin has some activity in vitro against Chiamydia trachomatis and Ureaplasma urealyticum, although not at levels attainable in serum. In this study, norfloxacin was administered (400 mg orally twice daily for 10 days) to men with acute nongonococcal urethritis. Of 25 men from whom C. trachomatis was initially isolated, 21 had the organism reisolated at the first follow-up visit posttreatment, and there were minimal changes in the number of inclusion-forming units in culture. Ultimately, all but 1 of the 22 men from whom C. trachomatis was initially isolated and who were monitored became clinical failures within 42 ± 7 days posttreatment. The clinical outcome was significantly better for men from whom U. urealyticum was initially isolated but from whom C. trachomatis was not isolated. Of 27 men, 17 became and stayed culture negative for U. urealyticum at follow-ups, and clinically, 15 no longer had nongonococcal urethritis. Of these 15, all 12 monitored until at least 42 ± 7 days posttreatment remained improved. Of 26 men from whom neither C. trachomatis nor U. urealyticum was initially isolated, 18 improved and all 15 who were monitored until at least 42 ± 7 days posttreatment remained improved. Thus, although norfloxacin attains high levels in urine and has good tissue penetration, it had essentially no activity against chlamydial urethritis in men. It had better, but incomplete, activity against U. urealyticum. For quinolones to show promise in vivo against C. trachomatis, either the MICs will need to be much lower or the levels attained in serum will have to be much higher.
The search for an antimicrobial agent active against the major bacterial genital pathogens continues. Norfloxacin at 600 mg orally, with the same dose repeated 4 h later, was highly effective in vivo against penicillin-susceptible and -resistant Neisseria gonorrhoeae (4) . The in vivo activity of norfloxacin against Chlamydia trachomatis and genital mycoplasmas is not known. In vitro, the MICs of norfloxacin against C. trachomatis (1, 5, 6, 8, 9, 13) and Ureaplasma urealyticum (1) have been 8 to 64 ,ug/ml. These levels exceed those attainable in serum, but because norfloxacin has good tissue penetration, urinary levels exceed the MICs, and in vitro results do not always accurately predict in vivo efficacy, a recent review concluded that norfloxacin should be evaluated for activity in nongonococcal urethritis (7) . In this study, norfloxacin (400 mg orally twice daily for 10 days) was administered to men with acute nongonococcal urethritis and its clinical and microbiological efficacy was evaluated.
MATERIALS AND METHODS
Study population. Men between the ages of 18 and 60 years were seen in the provincial Sexually Transmitted Disease Clinic in Vancouver between November 1984 and July 1985. Men with symptoms of urethritis for less than 1 month, obvious urethral discharge, and a mean of four or more polymorphonuclear leukocytes per field (in five fields; magnification, x1,000) on a Gram stain of urethral material (positive urethral smear) were included in the study if they had not voided for four or more hours, had not compounds, and subsequently had a negative urethral culture for N. gonorrhoeae.
Protocol. Men were administered a standard questionnaire, and a genital exam which included stripping the urethra from the base to the meatus at least three times was performed to detect urethral discharge and other abnormalities. A calcium alginate endourethral swab was then inserted 3 to 4 cm into the urethra for culture for C. trachomatis. Another calcium alginate endourethral swab was then inserted 1 cm more proximally for culture for U. urealyticum. The first 10 to 15 ml of urine was then collected for examination for pyuria and trichomonads and for culture for U. urealyticum. A midstream urine sample and serum sample were obtained for a safety profile (hematocrit, hemoglobin, leukocyte count and differential, blood urea nitrogen, serum aspartate aminotransferase, and urinalysis).
The men were then instructed to take 400 mg of oral norfloxacin twice daily for 10 days with a glass of water. They were also given a card on which to record when they took their medication, when they ate, changes in symptoms, and development of new symptoms (potential side effects).
An attempt was made to ensure that sexual partners were examined and treated either in the clinic or by their own physician. The men were then to return for follow-ups at 5 ± 2, 14 + 3, 28 ± 4, and 42 + 7 days after the end of treatment. On these occasions, they arrived without having voided for at least 4 h. They were questioned about symptoms, compliance, side effects, and sexual activity. They were then examined and had an endourethral swab obtained for a Gram stain and culture for C. trachomatis and another endourethral swab obtained for culture for U. urealyticum.
The first 10 to 15 ml of urine was collected for examination for pyuria and trichomonads and for culture for U. urealyticum. Safety profiles were repeated at the first follow-up visit. Laboratory investigations. Laboratory diagnosis was done by standard methods used previously (2, 3) . After the first 17 men were examined, the specimens for culture for C. trachomatis were immediately placed into 2-sucrose phosphate transport medium and frozen at -70°C within 30 min. Cultures for C. trachomatis were performed on cycloheximide-treated McCoy cells (10) in vials, with staining by iodine, and incorporated blind passes of negative cultures. Endourethral cultures for U. urealyticum were swabbed onto A7 agar (12) and then placed into U9 broth (11) . The first voided urine was swabbed onto A7 agar and then serially diluted in U9 broth. Organisms were identified by a color change in broth and by colony appearance on agar. Pyuria was defined as the presence of 20 or more polymorphonuclear leukocytes in two or more of five microscopic fields of the sediment of the first voided urine.
Statistical analysis. Fisher's exact test (n . 60) or chisquare analysis with Yates' correction (n 2 60) was used for statistical comparisons.
Definitions. Clinical failures were defined as patients with (i) symptoms of urethritis, (ii) urethral discharge that was clinically detectable and was more profuse or more purulent than a sparse clear discharge, and (iii) pyuria or a positive urethritis smear at any time posttreatment up to 42 + 7 days. These patients were further subdivided into those with persistent urethritis with failure at the first follow-up visit and those with recurrent urethritis who did not meet the criteria for failure until the second or a later follow-up visit. Microbiologic eradication was defined as negative cultures at all follow-up visits. Persistence was defined as a positive culture at the first follow-up visit. RESULTS Ninety-six men who met the diagnostic criteria for nongonococcal urethritis were enrolled in the study. For the first 17 men, the cultures for C. trachomatis were not reliable because of a problem with the initial handling in the clinic. These men were excluded from analysis of all but the toxicity data. Among the remaining 79 men, C. trachomatis was recovered from 27 (34%) and U. urealyticum was recovered from 34 (43%). Ten (13%) had both C. trachomatis and U. urealyticum isolated at the initial visit. The remaining 28 men (35%) had neither C. trachomatis nor U. As another measure of the in vivo effect of norfloxacin on C. trachomatis, the number of inclusion-forming units per cover slip in culture was compared for the pretreatment specimens and the first follow-up specimens, which were usually obtained within 5 days of the end of treatment. The number of inclusion-forming units remained virtually identical in 5 patients, decreased in 13 patients (including the 4 who were culture negative at the first follow-up visit), and rose in 7 patients. The study did not include a comparison group, but in contrast to the results with norfloxacin, 18 men who had C. trachomatis isolated at a follow-up visit and were treated with tetracycline (500 mg four times daily for 7 days) made one to three post-tetracycline treatment fol-low-up visits and cultures for C. trachomatis were negative at all visits.
Outcome for men who were initially C. trachomatis negative and U. urealyticum positive. Twenty-seven men who initially had U. urealyticum but not C. trachomatis isolated made one or more follow-up visits posttreatment. For 17, follow-up cultures were negative for U. urealyticum and stayed negative. One other man with a positive follow-up culture at the first visit was culture negative at two subsequent follow-up visits without intervening treatment. At the first follow-up visit, 12 of 27 (44%) men were clinical failures. This was significantly better than the results for men who initially had C. trachomatis isolated (X2 = 5.37, P < 0.05).
Although clinical failure was more frequent in men in whom U. urealyticum persisted at the first follow-up visit (6 of 10) than in those without persistence (6 of 17 [35%]), the difference was not statistically significant. Of the 15 men who were not clinical failures at the first follow-up visit, 12 were monitored for at least 42 + 7 days posttreatment, and none became a clinical treatment failure. Only one of these men was U. urealyticum positive at the first follow-up visit. One other man persistently positive for U. urealyticum had nongonococcal urethritis at the first follow-up visit but subsequently became normal without treatment.
Outcome for men who did not have C. trachomatis or U. urealyticum initially isolated. One or more follow-up visits were made by 26 men who had neither C. trachomatis nor U. urealyticum isolated at the initial visit. Of these, eight were failures at the first follow-up visit. This was significantly better than the results for men with C. trachomatis isolated initially (X2 = 10.47, P < 0.005) but was similar to the results for men who initially had U. urealyticum isolated without C. trachomatis. None of the eight men who failed had resumed sexual intercourse. Of the 18 men who initially improved, none of 15 monitored for at least 42 ± 7 days posttreatment subsequently failed. Three men who were not clinical failures became U. urealyticum positive after treatment. All had resumed sexual activity.
Side effects. Side-effect data were available for 95 men. No significant biochemical abnormalities were detected. In 17 men (18%), one or more minor symptoms were noted, but all were transient, often occurring on only one occasion and at most for 3 days. These included abdominal symptoms (nausea, loose bowel movements, flatulence, indigestion, or hyperacidity) in 12 patients, mood alteration, drowsiness, or light headedness in 6 patients, and headache in 2 patients. DISCUSSION Norfloxacin, at the doses tested, had virtually no in vivo effectiveness against C. trachomatis, as demonstrated not only by the high number of posttreatment positive cultures but also by its failure to markedly alter the number of inclusion-forming units in the immediate posttreatment cultures. When we evaluated norfloxacin against 10 isolates of C. trachomatis in 1981, the median MIC was 32 ,ug/ml, with a range of 16 to 64 p.g/ml (W. R. Bowie, unpublished data).
These results are similar to those of other studies (1, 5, 6, 8, 9, 13) . On the basis of the in vitro studies, good tissue penetration, and high concentrations of the drug in urine, Hooper and Wolfson proposed that norfloxacin might be useful for the treatment of nongonococcal urethritis (7). It clearly was not. This suggests that concentrations of antimicrobial agents in urine are probably not important in the treatment of urethral C. trachomatis infection in men.
The in vivo activity of norfloxacin against U. urealyticum is more encouraging and indicates that quinolones should be further evaluated. trachomatis in most men, it might be anticipated that attainable concentrations in serum will need to at least approximate or, better yet, exceed the MICs before in vivo efficacy will be noted. Because the newer quinolones also have better activity against genital mycoplasmas (1) , studies evaluating efficacy against C. trachomatis should concurrently assess activity against genital mycoplasmas.
